The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
After finishing at $16.54 in the prior trading day, Alignment Healthcare Inc (NASDAQ: ALHC) closed at $17.09, up 3.33%. In other words, the price has increased by $3.33 from its previous closing price. On the day, 2.33 million shares were traded. ALHC stock price reached its highest trading level at $17.11 during the session, while it also had its lowest trading level at $16.43.
Ratios:
Our goal is to gain a better understanding of ALHC by taking a closer look at its different ratios. In the meantime, Its Debt-to-Equity ratio is 2.34 whereas as Long-Term Debt/Eq ratio is at 2.34.
On July 31, 2025, Barclays Upgraded its rating to Equal Weight which previously was Underweight but kept the price unchanged to $13. Stephens Upgraded its Equal-Weight to Overweight on December 03, 2024, whereas the target price for the stock was revised from $13 to $17.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Sep 17 ’25 when General Atlantic (ALN HLTH), L sold 6,246,096 shares for $16.01 per share. The transaction valued at 99,999,997 led to the insider holds 24,596,079 shares of the business.
GENERAL ATLANTIC, L.P. sold 6,246,096 shares of ALHC for $99,999,997 on Sep 17 ’25. The Director now owns 24,596,079 shares after completing the transaction at $16.01 per share. On Sep 16 ’25, another insider, KONOWIECKI JOSEPH S, who serves as the Director of the company, sold 16,076 shares for $16.24 each. As a result, the insider received 261,074 and left with 1,110,973 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ALHC now has a Market Capitalization of 3384357120 and an Enterprise Value of 3210235904. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.01 while its Price-to-Book (P/B) ratio in mrq is 24.00. Its current Enterprise Value per Revenue stands at 0.962 whereas that against EBITDA is 408.115.
Stock Price History:
The Beta on a monthly basis for ALHC is 1.17, which has changed by 0.5466063 over the last 52 weeks, in comparison to a change of 0.1675967 over the same period for the S&P500. Over the past 52 weeks, ALHC has reached a high of $21.06, while it has fallen to a 52-week low of $9.15. The 50-Day Moving Average of the stock is 16.11%, while the 200-Day Moving Average is calculated to be 15.36%.
Shares Statistics:
The stock has traded on average 3.85M shares per day over the past 3-months and 6118510 shares per day over the last 10 days, according to various share statistics. A total of 197.96M shares are outstanding, with a floating share count of 150.59M. Insiders hold about 23.96% of the company’s shares, while institutions hold 74.17% stake in the company. Shares short for ALHC as of 1756425600 were 12051970 with a Short Ratio of 3.13, compared to 1753920000 on 13476373. Therefore, it implies a Short% of Shares Outstanding of 12051970 and a Short% of Float of 9.379999999999999.
Earnings Estimates
The stock of Alignment Healthcare Inc (ALHC) is currently drawing attention from 4.0 analysts actively involved in the ongoing evaluation and rating process.The consensus estimate for the next quarter is -$0.05, with high estimates of -$0.05 and low estimates of -$0.06.
Analysts are recommending an EPS of between $0.18 and $0.11 for the fiscal current year, implying an average EPS of $0.15. EPS for the following year is $0.32, with 4.0 analysts recommending between $0.4 and $0.26.
Revenue Estimates
10 analysts predict $980.9M in revenue for the current quarter. It ranges from a high estimate of $983.6M to a low estimate of $978M. As of the current estimate, Alignment Healthcare Inc’s year-ago sales were $692.43MFor the next quarter, 10 analysts are estimating revenue of $977.65M. There is a high estimate of $984.01M for the next quarter, whereas the lowest estimate is $968M.
A total of 10 analysts have provided revenue estimates for ALHC’s current fiscal year. The highest revenue estimate was $3.91B, while the lowest revenue estimate was $3.89B, resulting in an average revenue estimate of $3.9B. In the same quarter a year ago, actual revenue was $2.7BBased on 10 analysts’ estimates, the company’s revenue will be $4.97B in the next fiscal year. The high estimate is $5.47B and the low estimate is $4.77B.
